First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers

Annals of Oncology ◽

10.1016/s0923-7534(20)32010-x ◽

2012 ◽

Vol 23 ◽

pp. xi34

Author(s):

M.G. Kris ◽

T. Mok ◽

S.-H.I. Ou ◽

R.G. Martins ◽

D.-W. Kim ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lung Cancers ◽

Download Full-text

Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers

Annals of Oncology ◽

10.1016/s0923-7534(20)33849-7 ◽

2012 ◽

Vol 23 ◽

pp. ix400-ix401 ◽

Author(s):

M. Kris ◽

Z. Goldberg ◽

P.A. Janne ◽

D. Kim ◽

R. Martins ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Line Treatment ◽

Lung Cancers ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Line Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI

Annals of Oncology ◽

10.1093/annonc/mdx380.060 ◽

2017 ◽

Vol 28 ◽

pp. v485-v486 ◽

Author(s):

H. Husain ◽

R.G. Martins ◽

S.B. Goldberg ◽

P. Senico ◽

W. Ma ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Phase I Study ◽

Kinase Inhibitor ◽

Third Generation ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutant ◽

Download Full-text

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC)

Clinical Lung Cancer ◽

10.1016/j.cllc.2018.09.015 ◽

2019 ◽

Vol 20 (1) ◽

pp. 43-47 ◽

Author(s):

Yasir Y. Elamin ◽

Daniel R. Gomez ◽

Mara B. Antonoff ◽

Jacqulyne P. Robichaux ◽

Hai Tran ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Consolidation Therapy ◽

Small Cell Lung ◽

Download Full-text

Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance inROS1fusion positive lung cancers

10.1158/1538-7445.am2021-1111 ◽

2021 ◽

Author(s):

Sudarshan R. Iyer ◽

Igor Odintsov ◽

Adam J. Schoenfeld ◽

Hiroki Sato ◽

Evan Siau ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lung Cancers ◽

Inhibitor Resistance

Download Full-text

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Download Full-text

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyx161 ◽

2017 ◽

Vol 47 (12) ◽

pp. 1175-1181 ◽

Author(s):

Hiroki Ishihara ◽

Tsunenori Kondo ◽

Hironori Fukuda ◽

Kazuhiko Yoshida ◽

Kenji Omae ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Renal Function ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cell Carcinoma ◽

Kinase Inhibitor ◽

Tyrosine Kinase Inhibitor Therapy ◽

Function Change

Download Full-text

Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcino

International Journal of Urology ◽

10.1111/iju.13592 ◽

2018 ◽

Vol 25 (6) ◽

pp. 603-604 ◽

Author(s):

Jun Teishima ◽

Akio Matsubara

Keyword(s):

Editorial Comment ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Alanine Transaminase ◽

Prognostic Impact ◽

Aspartate Transaminase ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia

Value in Health ◽

10.1016/j.jval.2020.10.007 ◽

2020 ◽

Vol 23 (12) ◽

pp. 1671-1672

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Therapy Initiation ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text